Structure–activity relationships in a series of NPY Y5 antagonists: 3-amido-9-ethylcarbazoles, core-modified analogues and amide isosteres
作者:Marlys Hammond、Richard L. Elliott、Melissa L. Gillaspy、David C. Hager、Richard F. Hank、Janet A. LaFlamme、Robert M. Oliver、Paul A. DaSilva-Jardine、Ralph W. Stevenson、Christine M. Mack、James V. Cassella
DOI:10.1016/s0960-894x(03)00329-9
日期:2003.6
Beginning with carbazole la, the amide and alkyl substituents were optimized to maintain potency while adding solubilizing groups. Efforts to replace the 3-amino-9-ethylcarbazole core, a known carcinogen, used the SAR generated in the carbazole series for guidance and led to the synthesis of a number of core-modified analogues. In addition, an isosteric series, in which the amide was replaced with an imidazole, was prepared. Two potent new series lacking the putative toxicophore were identified from these endeavors. (C) 2003 Elsevier Science Ltd. All rights reserved.
CARBAZOLE DERIVATIVES AND THEIR USE AS NPY-5 ANTAGONISTS
申请人:Pfizer Products Inc.
公开号:EP1575934A1
公开(公告)日:2005-09-21
JP2006511530A
申请人:——
公开号:JP2006511530A
公开(公告)日:2006-04-06
US6949564B2
申请人:——
公开号:US6949564B2
公开(公告)日:2005-09-27
[EN] CARBAZOLE DERIVATIVES AND THEIR USE AS NPY-5 ANTAGONISTS<br/>[FR] DERIVES DE CARBAZOLE ET LEURS UTILISATIONS EN TANT QU'ANTAGONISTES DE NPY-5
申请人:PFIZER PROD INC
公开号:WO2004055002A1
公开(公告)日:2004-07-01
The present invention provides NPY-5 receptor antagonists having a Formula (IA). Methods and pharmaceutical compositions useful for treating diseases, conditions and/or disorders modulated by the above NPY-5 receptor antagonists are also provided.